Companies: 10,795·Total market cap: $144.5T
Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

OTLKNASDAQHealthcare● Active
$0.72
$-0.05(-7.04%)
Market Cap$29703369
P/E Ratio—
52W High$3.39
52W Low$0.161
Overview

Outlook Therapeutics, Inc.（OTLK）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

otlk · 股价预测 · 14 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 14 位华尔街分析师

SellBuy

Buy

14 位分析师

共识

评级分布

Strong Buy
0
Buy
7
Hold
7
Sell
0
Strong Sell
0
合计: 14 · 买入占比: 50.0%

12 个月目标价

High

$1.00

Consensus

$1.00

+38.5% upside

Low

$1.00

Median: $1 · Last Close: $0.72

Outlook Therapeutics, Inc.（OTLK）的分析师共识为 Buy，基于过去 3 个月内 14 位华尔街分析师的评级。OTLK 的 12 个月平均目标价为 $1.00，相对当前价 $0.72 代表 +38.5% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-09$0.72↑ 0.00%

1-day model range: $0.71–$0.74. Peak: $0.74 (+0.00%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

NEUTRAL

Based on 14 technical indicators

0%86%14%
0Buy
12Neutral
2Sell
RSI (14)50.0Neutral
MACDNEUTRAL

Refreshes daily from EOD close

Moving Averages · OTLK · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$0.78SELL
MA 10$0.00NEUTRAL
MA 20$0.00NEUTRAL
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $OTLK · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$0.76SELL
EMA 10$0.00NEUTRAL
EMA 20$0.00NEUTRAL
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $OTLK · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
BTIG2026-05-18
Downgrade ↓
Buy→Neutral
Ascendiant Capital2026-03-11
Maintains
Buy→Buy
HC Wainwright & Co.2026-02-18
Maintains
Neutral→Neutral
Chardan Capital2026-02-18
Maintains
Neutral→Neutral
Chardan Capital2026-01-05
Maintains
Neutral→Neutral
HC Wainwright & Co.2026-01-02
Maintains
Neutral→Neutral
Ascendiant Capital2025-12-22
Maintains
Buy→Buy
HC Wainwright & Co.2025-09-30
Maintains
Neutral→Neutral
Ascendiant Capital2025-09-22
Maintains
Buy→Buy
Guggenheim2025-08-29
Downgrade ↓
Buy→Neutral

Wall Street analysts have recently issued updated ratings on Outlook Therapeutics, Inc. (OTLK) stock. Of the recent 60 rating actions, 5 were upgrades and 11 were downgrades. 14 analysts currently cover OTLK.

分析师推荐趋势

Buy ratings1 → 0↓ 1
Hold ratings1 → 1
Sell ratings0 → 0

OTLK analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$16M

↓ 29.9% YoY

Revenue Next Year

$47M

↑ 193.4% YoY

EPS This Year

$-0.51

EPS Next Year

$-0.26

↓ 48.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast OTLK EPS of $-0.51 for the current fiscal year, based on estimates from 2 analysts. The OTLK revenue forecast is $16M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

OTLK 股价预测由两类独立数据源支撑：来自 14 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。OTLK 的共识目标价为 $1.00（+38.5% 上行空间），分析师共识为 Buy。

OTLK 的短期预测（明日）为 $0.72（+0.00%）。

Outlook Therapeutics, Inc. 在 NASDAQ 上市，代码 OTLK。OTLK 在 2027 年的整体展望偏积极，在覆盖分析师中约 50% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

OTLK 预测 · 8 个问题

根据 14 位华尔街分析师，OTLK 的 12 个月平均目标价为 $1.00，最高 $1.00、最低 $1.00。若有图表，中位目标价可在上方查看。相对当前价 $0.72，隐含约 +38.5% 的上行空间。

OTLK 目标价OTLK 分析师目标价OTLK 12个月目标价目标价 OTLK

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.